Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Elanco Animal Health IncELAN · Entity 3457 | Director | November 29, 2024 | December 03, 2024 |
| Minerva Neurosciences, Inc.NERV · Entity 6245 | Director | June 10, 2022 | June 28, 2022 |
| NovoCure LtdNVCR · Entity 4494 | Director · Executive Chairman | March 03, 2026 | March 05, 2026 |
| OptiNose, Inc.OPTN · Entity 79464 | Director | June 10, 2020 | June 12, 2020 |
| PROKIDNEY CORP.PROK · Entity 5181 | Director | May 28, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Elanco Animal Health Inc
Report date November 29, 2024 · Filed December 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 94,499 |
Reported balance
After 2024-11-29 transaction · row 1
1 source rowRow 1 · 2024-11-29 · Grant · Acquired 18,169 · Balance 94,499 F1: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors.
Minerva Neurosciences, Inc.
Report date June 10, 2022 · Filed June 28, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.32 · Expires 2032-06-09 | Direct | 2,500 |
Reported balance
After 2022-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-10 · Grant · Acquired 2,500 · Balance 2,500 F1: This option is granted to non-employee directors in accordance with the Issuer's compensation program for non-employee directors, which provides that each non-employee director is eligible to receive an annual option grant to purchase 2,500 shares of common stock per year. F2: On June 17, 2022, the Issuer completed a 1-for-8 reverse stock split of the Issuer's common stock ("Reverse Stock Split"). This amount has been adjusted to give effect to the Reverse Stock Split. F3: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 10, 2022 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option is granted to non-employee directors in accordance with the Issuer's compensation program for non-employee directors, which provides that each non-employee director is eligible to receive an annual option grant to purchase 2,500 shares of common stock per year.
F2: On June 17, 2022, the Issuer completed a 1-for-8 reverse stock split of the Issuer's common stock ("Reverse Stock Split"). This amount has been adjusted to give effect to the Reverse Stock Split.
F3: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 10, 2022 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date.
NovoCure Ltd
Report date March 03, 2026 · Filed March 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 200,000 |
Reported balance
After 2026-03-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-03-03 · Grant · Acquired 200,000 · Balance 200,000 F1: Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 400,284 |
Reported balance
After 2026-03-03 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-03-03 · Grant · Acquired 200,284 · Balance 400,284 F2: Represents vesting of performance-based restricted stock units. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 349,727 |
Reported balance
After 2026-03-03 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-03-03 · Sale · Disposed 50,557 · Balance 349,727 F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance-Based Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4: This transaction was executed in multiple trades at prices ranging from $12.299 USD to $13.277 USD; the price reported above reflects the weighted average sale price. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 328,397 |
Reported balance
After 2026-03-03 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-03-03 · Sale · Disposed 21,330 · Balance 328,397 F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance-Based Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F5: This transaction was executed in multiple trades at prices ranging from $13.35 USD to $13.52 USD; the price reported above reflects the weighted average sale price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.30 · Expires 2036-03-03 | Direct | 258,445 |
Reported balance
After 2026-03-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-03 · Grant · Acquired 258,445 · Balance 258,445 F6: Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.30 · Expires 2036-03-03 | Direct | 288,517 |
Reported balance
After 2026-03-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-03 · Grant · Acquired 30,072 · Balance 288,517 F6: Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates.
F2: Represents vesting of performance-based restricted stock units.
F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance-Based Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F4: This transaction was executed in multiple trades at prices ranging from $12.299 USD to $13.277 USD; the price reported above reflects the weighted average sale price.
F5: This transaction was executed in multiple trades at prices ranging from $13.35 USD to $13.52 USD; the price reported above reflects the weighted average sale price.
F6: Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date.
OptiNose, Inc.
Report date June 10, 2020 · Filed June 12, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.65 · Expires 2030-06-09 | Direct | 14,439 |
Reported balance
After 2020-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-10 · Grant · Acquired 14,439 · Balance 14,439 F1: The option vests and becomes exercisable on the earlier of (i) June 10, 2021 (the one-year anniversary of the date of grant) and (ii) the Issuer's 2021 annual meeting of stockholders, subject to continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable on the earlier of (i) June 10, 2021 (the one-year anniversary of the date of grant) and (ii) the Issuer's 2021 annual meeting of stockholders, subject to continued service with the Issuer.
PROKIDNEY CORP.
Report date May 28, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.81 · Expires 2036-05-28 | Direct | 135,000 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 135,000 · Balance 135,000 F1: These options were granted under the Issuer's non-employee director compensation policy. F2: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: These options were granted under the Issuer's non-employee director compensation policy.
F2: The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2020 Filed Jun 12, 2020 20:57 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001209191-20-036331 · doc4.xml · derivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-06-10 F1 · security: This option is granted to non-employee directors in accordance with the Company's compensation program for non-employee directors, which provides that each non-employee director is eligible to receive an annual option grant to purchase 20,000 shares of common stock per year. An additional option grant to purchase 20,000 shares of common stock was granted to the Reporting Person at the discretion of the Company's board of directors for such Reporting Person's service as lead independent director. F2 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 11, 2020 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 07:53 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantStock Option (Right to Buy) · Derivative | 14,439 | $5.65 Strike: $5.65 | $81,580.35 |
DisclosureSEC source: 0001494650-20-000068 · wf-form4_159196280835409.xml · derivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,439 Underlying: Common Stock · 14,439 shares Expires 2030-06-09 F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) June 10, 2021 (the one-year anniversary of the date of grant) and (ii) the Issuer's 2021 annual meeting of stockholders, subject to continued service with the Issuer. Read SEC document |
| May 11, 2020 Filed May 12, 2020 20:13 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 31,332 | $63.73 | $1,996,725.70 |
DisclosureSEC source: 0001645113-20-000076 · wf-form4_158931439083079.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 649,958 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units vested on May 8, 2020. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| May 08, 2020 Filed May 11, 2020 20:17 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 58,767 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000074 · wf-form4_158922826177084.xml · derivative · entry 6 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 58,767 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| May 08, 2020 Filed May 11, 2020 20:17 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 31,903 | $63.50 | $2,025,872.40 |
DisclosureSEC source: 0001645113-20-000074 · wf-form4_158922826177084.xml · nonDerivative · entry 4 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 681,290 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| May 08, 2020 Filed May 11, 2020 20:17 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 58,767 | $63.84 | $3,751,685.28 |
DisclosureSEC source: 0001645113-20-000074 · wf-form4_158922826177084.xml · nonDerivative · entry 3 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 713,193 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2020 Filed May 11, 2020 20:17 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Share Units · Derivative | 58,768 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000074 · wf-form4_158922826177084.xml · derivative · entry 5 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,767 Underlying: Ordinary Shares · 58,768 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| May 07, 2020 Filed May 11, 2020 20:17 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 30,993 | $64.74 | $2,006,517.81 |
DisclosureSEC source: 0001645113-20-000074 · wf-form4_158922826177084.xml · nonDerivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 654,426 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| May 07, 2020 Filed May 11, 2020 20:17 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 58,768 | $64.77 | $3,806,403.36 |
DisclosureSEC source: 0001645113-20-000074 · wf-form4_158922826177084.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 685,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2020 Filed May 7, 2020 20:41 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 58,768 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000071 · wf-form4_158888406331399.xml · derivative · entry 6 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,535 Underlying: Ordinary Shares · 58,768 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| May 06, 2020 Filed May 7, 2020 20:41 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 58,768 | $64.15 | $3,769,967.20 |
DisclosureSEC source: 0001645113-20-000071 · wf-form4_158888406331399.xml · nonDerivative · entry 4 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 626,651 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2020 Filed May 7, 2020 20:41 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 29,881 | $64.27 | $1,920,451.87 |
DisclosureSEC source: 0001645113-20-000071 · wf-form4_158888406331399.xml · nonDerivative · entry 3 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 567,883 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| May 05, 2020 Filed May 7, 2020 20:41 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 58,768 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000071 · wf-form4_158888406331399.xml · derivative · entry 5 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,303 Underlying: Ordinary Shares · 58,768 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| May 05, 2020 Filed May 7, 2020 20:41 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 30,283 | $62.47 | $1,891,718.44 |
DisclosureSEC source: 0001645113-20-000071 · wf-form4_158888406331399.xml · nonDerivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 597,764 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| May 05, 2020 Filed May 7, 2020 20:41 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 58,768 | $61.40 | $3,608,355.20 |
DisclosureSEC source: 0001645113-20-000071 · wf-form4_158888406331399.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 628,047 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2020 Filed May 6, 2020 21:52 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 58,768 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000070 · wf-form4_158880193641944.xml · derivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,071 Underlying: Ordinary Shares · 58,768 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| May 04, 2020 Filed May 6, 2020 21:52 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 58,768 | $60.48 | $3,554,288.64 |
DisclosureSEC source: 0001645113-20-000070 · wf-form4_158880193641944.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 569,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 20:18 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleRestricted Share Units | 4,320 | $69.53 | $300,386.88 |
DisclosureSEC source: 0001645113-20-000048 · wf-form4_158387150702220.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 510,511 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units vested on March 5, 2020. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 28, 2020 Filed Mar 2, 2020 22:13 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 3,893 | $72.22 | $281,133.00 |
DisclosureSEC source: 0001645113-20-000031 · wf-form4_158318721760895.xml · nonDerivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 514,831 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 22:13 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 9,259 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000031 · wf-form4_158318721760895.xml · derivative · entry 3 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,259 Underlying: Ordinary Shares · 9,259 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 22:13 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 9,259 | $79.45 | $735,627.55 |
DisclosureSEC source: 0001645113-20-000031 · wf-form4_158318721760895.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 518,724 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 21:19 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 133,777 | $95.00 | $12,708,815.00 |
DisclosureSEC source: 0001645113-20-000008 · wf-form4_157972796879829.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 509,465 F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Doyle. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:29 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 16,223 | $96.04 | $1,558,056.92 |
DisclosureSEC source: 0001645113-19-000015 · wf-form4_157480375888975.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 643,242 F1 · price: On November 25, 2019, Mr. Doyle sold 16,223 shares in multiple trades at prices ranging from $96.00 to $96.13. The price reported above reflects the weighted average sale price. Mr. Doyle hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 21:22 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 700 | $91.01 | $63,707.00 |
DisclosureSEC source: 0001645113-19-000011 · wf-form4_157445774481944.xml · nonDerivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 659,465 F2 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Doyle. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 21:22 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 149,300 | $90.36 | $13,490,016.43 |
DisclosureSEC source: 0001645113-19-000011 · wf-form4_157445774481944.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 660,165 F1 · price: On November 20, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Doyle, Mr. Doyle sold 149,300 shares in multiple trades at prices ranging from $90.00 to $91.00. The price reported above reflects the weighted average sale price. Mr. Doyle hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 12, 2019 Filed Nov 13, 2019 21:31 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,100 | $82.14 | $172,498.20 |
DisclosureSEC source: 0001645113-19-000005 · wf-form4_157368070239649.xml · nonDerivative · entry 3 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 809,465 F3 · price: On November 12, 2019, Mr. Doyle sold 2,100 shares in multiple trades at prices ranging from $82.08 to $82.24. The price reported above reflects the weighted average sale price. Mr. Doyle hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 12, 2019 Filed Nov 13, 2019 21:31 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 11,118 | $81.59 | $907,117.62 |
DisclosureSEC source: 0001645113-19-000005 · wf-form4_157368070239649.xml · nonDerivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 811,565 F2 · price: On November 12, 2019, Mr. Doyle sold 11,118 shares in multiple trades at prices ranging from $81.07 to $82.07. The price reported above reflects the weighted average sale price. Mr. Doyle hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 21:31 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 29,782 | $80.11 | $2,385,776.46 |
DisclosureSEC source: 0001645113-19-000005 · wf-form4_157368070239649.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 822,683 F1 · price: On November 11, 2019, Mr. Doyle sold 29,782 shares in multiple trades at prices ranging from $80.00 to $80.45. The price reported above reflects the weighted average sale price. Mr. Doyle hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 30, 2019 Filed Aug 1, 2019 20:12 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 10,412 | $0.00 Strike: $83.30 | $0.00 |
DisclosureSEC source: 0001209191-19-044010 · doc4.xml · derivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,412 Underlying: Ordinary Shares · 10,412 shares Expires 2029-07-30 F1 · security: These equity awards were granted to Mr. Doyle in recognition of his accomplishments related to Medicare coverage and pricing. F3 · derivative.exercise_date: Options to buy 10,412 ordinary shares will vest and become exercisable in equal installments on each of July 30, 2020, 2021, 2022 and 2023, subject to the reporting person's continued employment through such dates. Read SEC document |
| July 30, 2019 Filed Aug 1, 2019 20:12 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Stock Units | 6,002 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-044010 · doc4.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 852,465 F1 · security: These equity awards were granted to Mr. Doyle in recognition of his accomplishments related to Medicare coverage and pricing. F2 · shares: One-third of these restricted stock units are scheduled to vest on each of July 30, 2020, 2021 and 2022, subject to the reporting person's continued employment through such dates. Read SEC document |
| June 27, 2019 Filed Jul 1, 2019 20:43 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | PurchaseCommon Stock | 3,500 | $5.50 | $19,250.00 |
DisclosureSEC source: 0001209191-19-039748 · doc4.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,111 Read SEC document |
| June 12, 2019 Filed Jun 13, 2019 20:28 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001209191-19-036792 · doc4.xml · derivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-06-11 F1 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 12, 2019 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 10:48 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantStock Option (Right to Buy) · Derivative | 14,439 | $6.60 Strike: $6.60 | $95,297.40 |
DisclosureSEC source: 0001494650-19-000053 · wf-form4_156017810578834.xml · derivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,439 Underlying: Common Stock · 14,439 shares Expires 2029-06-05 F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) June 6, 2020 (the one-year anniversary of the date of grant) and (ii) the Issuer's 2020 annual meeting of stockholders, subject to continued service with the Issuer. Read SEC document |
| May 31, 2019 Filed May 31, 2019 21:39 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.21 | $0.00 |
DisclosureSEC source: 0001209191-19-033703 · doc4.xml · derivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-05-30 F1 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following May 31, 2019 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 20:08 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 48,100 | $53.07 | $2,552,522.70 |
DisclosureSEC source: 0001209191-19-033865 · doc4.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 846,463 F1 · price: On May 30, 2019, Mr. Doyle sold 48,100 shares in multiple trades at prices ranging from $53.00 to $53.42. The price reported above reflects the weighted average sale price. Mr. Doyle hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 29, 2019 Filed May 31, 2019 20:12 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,900 | $53.10 | $100,880.50 |
DisclosureSEC source: 0001209191-19-033631 · doc4.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 894,563 F1 · price: On May 29, 2019, Mr. Doyle sold 1,900 shares in multiple trades at prices ranging from $53.00 to $53.24. The price reported above reflects the weighted average sale price. Mr. Doyle hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 09, 2019 Filed May 10, 2019 20:13 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 31,460 | $47.37 | $1,490,386.04 |
DisclosureSEC source: 0001209191-19-028879 · doc4.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 896,463 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| May 08, 2019 Filed May 9, 2019 20:20 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 58,768 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-028476 · doc4.xml · derivative · entry 6 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,839 Underlying: Ordinary Shares · 58,768 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| May 08, 2019 Filed May 9, 2019 20:20 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 58,768 | $47.62 | $2,798,532.16 |
DisclosureSEC source: 0001209191-19-028476 · doc4.xml · nonDerivative · entry 4 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 927,923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 08, 2019 Filed May 9, 2019 20:20 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 32,218 | $47.52 | $1,531,031.58 |
DisclosureSEC source: 0001209191-19-028476 · doc4.xml · nonDerivative · entry 3 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 869,155 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the Issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| May 08, 2019 Filed May 10, 2019 20:13 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 35,000 | $0.00 Strike: $47.56 | $0.00 |
DisclosureSEC source: 0001209191-19-028879 · doc4.xml · derivative · entry 3 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Ordinary Shares · 35,000 shares Expires 2029-05-08 F3 · derivative.exercise_date: Options to buy 35,000 ordinary shares will fully vest and become exercisable on May 8, 2022 if (i) the closing price of the Company's ordinary shares is at least $71.34 for a period of at least twenty (20) consecutive trading days at any time between May 8, 2021 and May 8, 2022 and (ii) Mr. Doyle has been continuously employed by the Company through May 8, 2022. Read SEC document |
| May 08, 2019 Filed May 10, 2019 20:13 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 115,060 | $0.00 Strike: $47.56 | $0.00 |
DisclosureSEC source: 0001209191-19-028879 · doc4.xml · derivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,060 Underlying: Ordinary Shares · 115,060 shares Expires 2029-05-08 F2 · derivative.exercise_date: Options to buy 115,060 ordinary shares will fully vest and become exercisable on May 8, 2022 if (i) the closing price of the Company's ordinary shares is at least $59.45 for a period of at least twenty (20) consecutive trading days at any time between May 8, 2021 and May 8, 2022 and (ii) Mr. Doyle has been continuously employed by the Company through May 8, 2022. Read SEC document |
| May 07, 2019 Filed May 9, 2019 20:20 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 58,768 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-028476 · doc4.xml · derivative · entry 5 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,607 Underlying: Ordinary Shares · 58,768 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| May 07, 2019 Filed May 9, 2019 20:20 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 58,768 | $48.92 | $2,874,930.56 |
DisclosureSEC source: 0001209191-19-028476 · doc4.xml · nonDerivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 901,373 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2019 Filed May 9, 2019 20:20 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 32,098 | $47.67 | $1,530,111.66 |
DisclosureSEC source: 0001209191-19-028476 · doc4.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 842,605 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the Issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| May 06, 2019 Filed May 7, 2019 20:28 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 58,768 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-027977 · doc4.xml · derivative · entry 3 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,375 Underlying: Ordinary Shares · 58,768 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| May 06, 2019 Filed May 7, 2019 20:28 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 58,768 | $48.89 | $2,873,167.52 |
DisclosureSEC source: 0001209191-19-027977 · doc4.xml · nonDerivative · entry 2 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 874,703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2019 Filed May 7, 2019 20:28 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 29,038 | $48.07 | $1,395,914.74 |
DisclosureSEC source: 0001209191-19-027977 · doc4.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 815,935 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale is mandated by the Issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| May 03, 2019 Filed May 6, 2019 21:48 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 58,768 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-027818 · doc4.xml · derivative · entry 5 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,143 Underlying: Ordinary Shares · 58,768 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| May 03, 2019 Filed May 6, 2019 21:48 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 58,768 | $44.60 | $2,621,052.80 |
DisclosureSEC source: 0001209191-19-027818 · doc4.xml · nonDerivative · entry 3 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 844,973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.